Latest Conference Articles

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”

E. Anders Kolb, MD, outlines the challenges in diagnosing pediatric cancers and explains how molecular events define disease outcomes.

The modeled and lifetime QALY costs in the facility and out of the facility were $181,144 and $107,965, respectively, for PPV.

A population-based cohort study identified that patients with insomnia developed AMD at a rate 0.7% higher than those who did not.

How improvements to patient education, drug costs, and biosimilar therapy availability could keep patients with retina disease away from risky procedures.

Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.

The number of anti-VEGF injections patients underwent per 28 days decreased from 0.322 to 0.047 after FAc implantation.

The director of the Section of Uveitis and Vasculitis at Emory University spoke about the potential of this novel delivery method in conditions such as uveitis and retinal vein occlusion.

Though cell therapies have gained FDA approval to treat any ocular disease, companies have marketed predominately to patients with AMD, with procedures that could lead to blindness.

Though the 2 dosing regimens had comparable visual acuity improvements over 24 months, patients given ranibizumab once-monthly received treatment nearly 6 more times on average.

The treatment, traditionally used for cancer, not only improved BVCA measurements but also resulted in the number of injections patients needed.

At the final follow-up in year 5, 16.5% of eyes had lost >15 ETDRS letters, compared to 33% that had gained >15 ETDRS letters.

Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.

The analysis suggests that patients with neovascular AMD may be undertreated in clinical practice settings.

E. Anders Kolb, MD, emphasizes the difference between pediatric and adult cancers and the need to develop new treatments developed specifically for children.

Pauline Funchain, MD, discusses the use of multiplex germline testing for rare diseases and cancers and explains the benefits of uncovering genetic factors.

Owen A. O’Connor, MD, PhD, outlines the importance of clinical trials and reviewed strides made in lymphoma treatments.

Peter Toth, MD, spoke about the importance of noting elevated triglycerides in patients at risk for cardiovascular conditions.

The study revealed for the first time that triglycerides can be utilized as an independent predictor of cardiovascular risk—a landmark moment.

Dr Meletios A. Dimopoulos, discusses the use of ibrutinib combined with rituximab for the treatment of patients with Waldenström macroglobulinemia.

The poster presentations included a meta-analysis of 17 studies analyzing the cost-effectiveness and performance of the CGM system and a real-world examination of the trends its use.

Tim Dunn, PhD, discussed the benefits that the Freestyle Libre continuous glucose monitoring system provides for both the patients and providers

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

Murray Stewart, MD, spoke about his research into the hormone leptin—a major player in appetite and metabolism, with much that's still misunderstood about it.

The addition of features such as Bluetooth and Wi-Fi connectivity, in addition to cloud-to-cloud integration, is essential to improving diabetes devices.

Across the 6-month duration of the trial, weight loss was maintained across all dose levels, with patients that had the lowest baseline leptin levels benefitting the most.

How telehealth-friendly devices could change standard of diabetes care — with the help of physicians, patients, and the overall health care system.